It enables the seller of the stock -- that is, management -- to price the issue right. It also enables management to pick the right investor.

We are pleased with our performance in 2005. The year was highlighted by the filing of the new drug application on NRP104, our lead compound under development, for the treatment of Attention Deficit Hyperactivity Disorder in pediatric populations. We believe that this advancement together with the progress on our other pipeline products positions us well for future growth. Looking forward, we anticipate receiving approval from the FDA on NRP104 in the second half of 2006 and making IND filings on NRP409 and NRP388, the two most advanced candidates in our preclinical pipeline, by the end of the second quarter of 2006. In addition, we plan to continue to develop NRP290, our second most advanced compound, and other drug products in our research pipeline.

We were very excited about our story.

We have seen a tremendous increase in terms of the interest we are getting here.

If you're on the management track, the right answer is to say you aspire to senior management because of your big-picture vision and drive to make it happen. If you are not yet in management, you need to say that one day you plan to take on that type of role.

Emergency management is in such a state of disarray right now that it could take a couple of years.